Matches in Wikidata for { <http://www.wikidata.org/entity/Q74281464> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- Q74281464 description "clinical trial" @default.
- Q74281464 description "ensayu clínicu" @default.
- Q74281464 description "klinisch onderzoek" @default.
- Q74281464 description "клінічне випробування" @default.
- Q74281464 description "կլինիկական փորձարկում" @default.
- Q74281464 name "A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation" @default.
- Q74281464 name "A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation" @default.
- Q74281464 type Item @default.
- Q74281464 label "A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation" @default.
- Q74281464 label "A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation" @default.
- Q74281464 prefLabel "A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation" @default.
- Q74281464 prefLabel "A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation" @default.
- Q74281464 P1050 Q74281464-54B48D8B-200C-4FC9-8147-728C60006CC9 @default.
- Q74281464 P1132 Q74281464-B1CACFE7-7BA1-4E32-A068-932B82260D10 @default.
- Q74281464 P1476 Q74281464-A6962AF6-4D3A-43C2-B7EC-3F0451439085 @default.
- Q74281464 P17 Q74281464-08F6E984-A532-4F60-86E8-444D52E9EC54 @default.
- Q74281464 P17 Q74281464-34124E78-1F81-4ACF-8F57-41859293778D @default.
- Q74281464 P17 Q74281464-4C467CD7-C9BE-480A-84DA-EB700192D250 @default.
- Q74281464 P17 Q74281464-4ECFE999-B928-45F7-A5B6-24EB20C2615C @default.
- Q74281464 P17 Q74281464-57D89DA3-7DF0-4ED1-8BBA-928D636E39ED @default.
- Q74281464 P17 Q74281464-5EB27C7C-913F-4ED9-986F-ADEC36838D6D @default.
- Q74281464 P17 Q74281464-611663E8-E0E4-4E32-A328-D139F5C06063 @default.
- Q74281464 P17 Q74281464-6EC01850-21CA-48A2-B4C9-4ED19C56FEF6 @default.
- Q74281464 P17 Q74281464-73DA37BA-0D81-4E97-8494-25BE05D7229E @default.
- Q74281464 P17 Q74281464-7FEB5A3B-93A0-4CD4-AF7E-18167C715C98 @default.
- Q74281464 P17 Q74281464-8D99657B-56E0-46DA-A857-E5B8CFED31EE @default.
- Q74281464 P17 Q74281464-A4FB043E-38BD-4313-BE1A-4475DBEE81E9 @default.
- Q74281464 P17 Q74281464-BBD86B1A-29C8-4C0B-B17B-D26E17B09155 @default.
- Q74281464 P17 Q74281464-BC353B4A-950E-4A23-BDF3-8207A1BB0855 @default.
- Q74281464 P17 Q74281464-C881945E-7FEF-4F71-A2E1-42DE8D85B077 @default.
- Q74281464 P17 Q74281464-D47DD43D-E16F-4E5D-A4B9-FBE997C57134 @default.
- Q74281464 P17 Q74281464-EE2B84AB-0D39-493C-BC8F-87829C2EE0F5 @default.
- Q74281464 P1813 Q74281464-5CC390BB-710F-4EB4-B244-97C3ABF7615B @default.
- Q74281464 P2899 Q74281464-A4163192-D744-413C-9DA9-CCA238F81BF9 @default.
- Q74281464 P3098 Q74281464-340704EA-63BF-422C-AF3A-CFBC0D71FD33 @default.
- Q74281464 P31 Q74281464-CDEB3AC9-22DD-4391-B291-484E3E09FCFE @default.
- Q74281464 P4844 Q74281464-FA319D65-2E53-4997-999E-524BEE0D2716 @default.
- Q74281464 P580 Q74281464-1661DF8F-F71C-48CD-A27D-98EDD8CC1E5A @default.
- Q74281464 P582 Q74281464-37A52F26-1573-4A35-AF47-76B335674856 @default.
- Q74281464 P6099 Q74281464-DE8CAC35-65B7-498E-B6C2-C6A2593C7EBF @default.
- Q74281464 P8363 Q74281464-DDA7612E-8A4C-4138-9295-099CB9627D75 @default.
- Q74281464 P859 Q74281464-703ADF92-6BCE-499D-A22E-1DFC6459CF56 @default.
- Q74281464 P1050 Q33525 @default.
- Q74281464 P1132 "+662" @default.
- Q74281464 P1476 "A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation" @default.
- Q74281464 P17 Q155 @default.
- Q74281464 P17 Q16 @default.
- Q74281464 P17 Q17 @default.
- Q74281464 P17 Q183 @default.
- Q74281464 P17 Q30 @default.
- Q74281464 P17 Q31 @default.
- Q74281464 P17 Q334 @default.
- Q74281464 P17 Q38 @default.
- Q74281464 P17 Q40 @default.
- Q74281464 P17 Q408 @default.
- Q74281464 P17 Q419 @default.
- Q74281464 P17 Q43 @default.
- Q74281464 P17 Q664 @default.
- Q74281464 P17 Q8646 @default.
- Q74281464 P17 Q865 @default.
- Q74281464 P17 Q869 @default.
- Q74281464 P17 Q96 @default.
- Q74281464 P1813 "IMbrave050" @default.
- Q74281464 P2899 "+18" @default.
- Q74281464 P3098 "NCT04102098" @default.
- Q74281464 P31 Q30612 @default.
- Q74281464 P4844 Q413299 @default.
- Q74281464 P580 "2019-12-12T00:00:00Z" @default.
- Q74281464 P582 "2023-03-12T00:00:00Z" @default.
- Q74281464 P6099 Q42824827 @default.
- Q74281464 P8363 Q78089383 @default.
- Q74281464 P859 Q212646 @default.